GSK plc (LSE/NYSE: GSK), a prominent pharmaceutical company with a market capitalization of $73 billion and impressive gross margins of 72%, announced today that the China National Medical (TASE ...

Already billed as a potential blockbuster, Amgen and AstraZeneca’s Tezspire has turned in strong clinical data in chronic ...

(Alliance News) - GSK PLC on Thursday said its monoclonal antibody Nucala, also known as mepolizumab, has been accepted for review in China. The London-based pharmaceutical company said the China ...

Despite early success, Verona's lack of specific 2025 guidance and competition from Dupixent and other drugs raise concerns.

GSK plc (LSE/NYSE: LON:GSK), a prominent pharmaceutical company with a market capitalization of $73 billion and impressive gross margins of 72%, announced today that the China National Medical ...

GSK plc announced that the China National Medical Products Administration has accepted for review the new drug application for the use of Nucala (mepolizumab), a monoclonal antibody that targets ...

GSK is enlisting the aid of China’s Chongqing Zhifei Biological Products (Zhifei) to drive sales of its most important vaccine, Shingrix, in China over the next few years, and may also call upon ...

In this article, we are going to take a look at where GSK plc (NYSE:GSK ... he did say that anything coming out of Europe or China would obviously be fair game. The pharmaceutical companies ...

So, one of the milestones that I want to note right at the beginning of the article is that GSK announced that on January 28, 2025, regulatory authorities in China, Japan, and Europe accepted ...

Secondly and more tangibly, China is a massive center for contract ... Formerly known as GlaxoSmithKline, GSK plc (NYSE:GSK) is a global healthcare and pharmaceutical corporation that develops ...

Two conferences were held in Hanoi and Ho Chi Minh City in early March to discuss shingles in comorbid patients.